CN112996774A - 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 - Google Patents

2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN112996774A
CN112996774A CN202080005989.9A CN202080005989A CN112996774A CN 112996774 A CN112996774 A CN 112996774A CN 202080005989 A CN202080005989 A CN 202080005989A CN 112996774 A CN112996774 A CN 112996774A
Authority
CN
China
Prior art keywords
groups
compound
group
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080005989.9A
Other languages
English (en)
Other versions
CN112996774B (zh
Inventor
郁楠
杨方龙
彭伟
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Shengdi Pharmaceutical Co ltd
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112996774A publication Critical patent/CN112996774A/zh
Application granted granted Critical
Publication of CN112996774B publication Critical patent/CN112996774B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本公开涉及2‑氧代‑1,2‑二氢吡啶类衍生物、其制备方法及其在医药上的应用。特别地，本公开涉及通式(IG)所示的2‑氧代‑1,2‑二氢吡啶类衍生物或其前药、其制备方法及含有该衍生物或其前药的药物组合物，以及其作为NaV抑制剂的用途和其在制备治疗和/或预防疼痛和疼痛相关疾病的药物中的用途。其中通式(IG)的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202080005989.9A 2019-01-25 2020-01-22 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 Active CN112996774B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910072432 2019-01-25
CN2019100724326 2019-01-25
PCT/CN2020/073668 WO2020151728A1 (zh) 2019-01-25 2020-01-22 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN112996774A true CN112996774A (zh) 2021-06-18
CN112996774B CN112996774B (zh) 2022-11-22

Family

ID=71735671

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080005989.9A Active CN112996774B (zh) 2019-01-25 2020-01-22 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用

Country Status (3)

Country Link
CN (1) CN112996774B (zh)
TW (1) TW202043200A (zh)
WO (1) WO2020151728A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520649A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド （２ｒ，３ｓ，４ｓ，５ｒ）－４－［［３－（３，４－ジフルオロ－２－メトキシ－フェニル）－４，５－ジメチル－５－（トリフルオロメチル）テトラヒドロフラン－２－カルボニル］アミノ］ピリジン－２－カルボキサミドを含む固体剤形及び投与レジメン
EP4347033A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
WO2022256702A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
AR126073A1 (es) 2021-06-04 2023-09-06 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105026373A (zh) * 2013-01-31 2015-11-04 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
CN105814067A (zh) * 2013-12-13 2016-07-27 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺的前药
WO2018213426A1 (en) * 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
WO2019014352A1 (en) * 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105026373A (zh) * 2013-01-31 2015-11-04 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
CN105814067A (zh) * 2013-12-13 2016-07-27 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺的前药
WO2018213426A1 (en) * 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
WO2019014352A1 (en) * 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS

Also Published As

Publication number Publication date
TW202043200A (zh) 2020-12-01
CN112996774B (zh) 2022-11-22
WO2020151728A1 (zh) 2020-07-30

Similar Documents

Publication Publication Date Title
CN112996774B (zh) 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN112955436B (zh) 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用
CN112390745B (zh) 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
CN112996776B (zh) 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用
TW202115038A (zh) 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
WO2021197464A1 (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
ES2668721T3 (es) Derivado de ácido de cicloalquilo, método de preparación y aplicación farmacéutica del mismo
BR112019011121A2 (pt) compostos de benzenossulfonamida e seu uso como agentes terapêuticos
TW202214259A (zh) 一種選擇性ＮａＶ抑制劑的前藥及其晶型
JP2021535134A (ja) ヘテロアリール置換スルホンアミド化合物および治療剤としてのそれらの使用
CN111511745A (zh) 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
BR112020004611A2 (pt) derivado de indol formamida substituído por átomo de deutério, método de preparação do mesmo e aplicações médicas do mesmo
CN113874367A (zh) 吲唑类衍生物、其制备方法及其在医药上的应用
CN102030771B (zh) 作为trpv1阻断剂的化合物、药物组合物及其医药用途
CN112574212B (zh) 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
TW202144342A (zh) 芳甲醯胺類化合物及其製備方法和醫藥用途
RU2791534C2 (ru) Производное 6-оксо-1,6-дигидропиридазина, способ его получения и его применение в медицине
TW202114989A (zh) 吡啶苯甲醯胺類衍生物、其製備方法及其在醫藥上的應用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230512

Address after: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee after: Shandong Shengdi Pharmaceutical Co.,Ltd.

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right